CIK 0002093101 · <br>Emerging growth company
Atrium Therapeutics, Inc.
Sign in to watch- Ticker
- RNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 394639499
- Phone
- 6198760700
- Business address
- 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-18 | Younis Husam Chief Scientific Officer | Shares withheld for taxes | −11,216 | $8.95 | $100K | 41,441 |
| 2026-09-18 | Hughes Steven George Chief Medical Officer | Shares withheld for taxes | −21,459 | $8.95 | $192K | 51,638 |
| 2026-09-18 | Flanagan W. Michael Director | Shares withheld for taxes | −22,812 | $8.95 | $204K | 31,974 |
| 2026-09-18 | Boyce Sarah Director | Shares withheld for taxes | −126,418 | $8.95 | $1.1M | 138,668 |
| 2026-09-18 | Kenney Stephanie See Remarks | Shares withheld for taxes | −2,375 | $8.95 | $21K | 33,085 |
| 2026-09-18 | Gallagher Kathleen P. See Remarks | Shares withheld for taxes | −11,632 | $8.95 | $104K | 119,729 |
| 2026-09-18 | Winslow Brendan R. Chief Financial Officer | Shares withheld for taxes | −6,742 | $8.95 | $60K | 36,859 |
| 2026-09-18 | Hoyos Rocio Martin Chief Strategy Officer | Shares withheld for taxes | −8,320 | $8.95 | $74K | 38,340 |
| 2026-04-20 | Kenney Stephanie See Remarks | Grant or award | +30,000 | 35,460 | ||
| 2026-04-20 | Kenney Stephanie See Remarks | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2026-04-20 | Hughes Steven George Chief Medical Officer | Grant or award | +30,000 | 73,097 | ||
| 2026-04-20 | Hughes Steven George Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2026-04-20 | Winslow Brendan R. Chief Financial Officer | Grant or award | +30,000 | 43,601 | ||
| 2026-04-20 | Winslow Brendan R. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2026-04-20 | Gallagher Kathleen P. See Remarks | Grant or award | +102,500 | 131,361 | ||
| 2026-04-20 | Gallagher Kathleen P. See Remarks | Grant or award · Stock Option (Right to Buy) | +205,000 | 205,000 | ||
| 2026-04-20 | Hoyos Rocio Martin Chief Strategy Officer | Grant or award | +30,000 | 46,660 | ||
| 2026-04-20 | Hoyos Rocio Martin Chief Strategy Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2026-04-20 | Younis Husam Chief Scientific Officer | Grant or award | +30,000 | 52,657 | ||
| 2026-04-20 | Younis Husam Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 |
Page 1 of 2 · 25 trades